桉树幼苗对难溶性磷的吸收及其根系对低磷胁迫的响应

以‘广林9号’桉树幼苗为试验材料,采用水培和土培试验方法研究了桉树幼苗对难溶性磷酸盐的吸收及其在低磷胁迫下的根构型和根系的生理反应,以揭示桉树高效吸收磷素的机制。结果显示:(1)桉树幼苗在含磷酸铝的缺磷培养液中吸收的磷达4.24mg/株,与供应水溶性磷和磷酸钙处理的相当。(2)土壤缺磷或仅在上土层(0~20cm)施磷肥处理均有利于桉树幼苗浅层根的分布,使根表面积及根数在上土层与下层(20~40cm)比值明显增高。(3)桉树幼苗根尖的H+-ATPase活性在缺磷处理15d后显著提高,其根尖周围的溴甲酚紫指示剂变黄,根基环境明显酸化;根尖分泌的酸性磷酸酶活性在低磷胁迫也显著提升,且随着处理时间(10、15、20d)的延长而进一步提高;铝和低磷胁迫能明显诱导桉树根系分泌草酸,其分泌量显著高于对照和缺磷处理。研究结果表明,桉树幼苗具有较强的难溶性磷吸收能力,而在缺磷及磷铝胁迫下根系的浅层化、根尖酸化及根分泌的酸性磷酸酶及草酸量增加可能是桉树幼苗适应酸性土壤铝毒和缺磷环境的重要机制。     

融合位置特征与序列进化信息的磷酸化位点预测

磷酸化是蛋白质翻译后的主要修饰,可分为激酶特异性和非激酶特异性两种类型．以非激酶特异性磷酸化位点Dou数据集为基础,本文发展了一种基于位置的卡方差表特征χ²-pos,融合伪氨基酸序列进化信息PsePSSM表征序列,构建正负样本均衡的支持向量机分类器,S, T, Y独立测试Matthew相关系数、ROC曲线下面积分及准确率分别达到了(0.59、0.87、79.74%),(0.55、0.85、77.68%)和(0.50、0.81、75.22%),明显优于文献报道结果． χ²-pos、PsePSSM两种特征的融合在蛋白质磷酸化位点预测中有广泛应用前景．     

循环包装回收技术在筛选肝癌细胞相关耐药基因中的应用

肝癌先天性多表达多药耐药基因,严重影响肝癌的化疗效果,筛选肝癌细胞中的耐药基因,研究其耐药机制有助于提高肝癌化疗效果,提高肝癌的治愈率。首先构建肝癌细胞逆转录病毒的cDNA文库,感染成纤维细胞,使得逆转录病毒基因整合进细胞,加药筛选,存活细胞中的基因再次包装成病毒,用于下一轮筛选。采用循环包装回收(Cyclical packaging rescue,CPR)技术进行肝癌细胞耐药基因的筛选即是通过病毒包装将基因从细胞中钓取出来,相比于常规筛选方法,仅通过一轮筛选可能会出现很多假阳性基因,采用CPR技术则是通过多轮筛选,很大程度减少了假阳性细胞的出现。通过该方法经过四轮筛选获得核糖体蛋白S11(RPS11)、核糖体蛋白L6(RPL6)、核糖体蛋白L11(RPL11)、核糖体蛋白L24(RPL24)等几种基因,经初步检测,增加了细胞的耐药性。     

Deoxyribonuclease 1-like 3 Inhibits Hepatocellular Carcinoma Progression by Inducing Apoptosis and Reprogramming Glucose Metabolism

HCC has remained one of the challenging cancers to treat, owing to the paucity of drugs targeting the critical survival pathways. Considering the cancer cells are deficient in DNase activity, the increase of an autonomous apoptisis endonuclease should be a reasonable choice for cancer treatment. In this study, we investigated whether DNASE1L3, an endonuclease implicated in apoptosis, could inhibit the progress of HCC. We found DNASE1L3 was down-regulated in HCC tissues, whereas its high expression was positively associated with the favorable prognosis of patients with HCC. Besides, serum DNASE1L3 levels were lower in HCC patients than in healthy individuals. Functionally, we found that DNASE1L3 inhibited the proliferation of tumor cells by inducing G0/G1 cell cycle arrest and cell apoptosis in vitro. Additionally, DNASE1L3 overexpression suppressed tumor growth in vivo. Furthermore, we found that DNASE1L3 overexpression weakened glycolysis in HCC cells and tissues via inactivating the rate-limiting enzymes involved in PTPN2-HK2 and CEBPβ-p53-PFK1 pathways. Finally, we identified the HBx to inhibit DNASE1L3 expression by up-regulating the expression of ZNF384. Collectively, our findings demonstrated that DNASE1L3 could inhibit the HCC progression through inducing cell apoptosis and weakening glycolysis. We believe DNASE1L3 could be considered as a promising prognostic biomarker and therapeutic target for HCC.     

Aldosterone induction of hepatic stellate cell contraction through activation of RhoA/ROCK-2 signaling pathway

The RhoA/ROCK-2 signaling pathway is necessary for activated hepatic stellate cell (HSC) contraction. HSC contraction plays an important role in the pathogenesis of cirrhosis and portal hypertension. This study investigated whether aldosterone contributes to HSC contraction by activation of the RhoA/ROCK-2 signaling pathway. Primary HSCs were isolated from Sprague-Dawley rats via in situ pronase/collagenase perfusion. We found that aldosterone enhanced the contraction of a collagen lattice seeded with HSCs. This induced contraction was suppressed by the mineralcorticoid receptor (MR) inhibitor spironolactone, the ROCK-2 inhibitor Y27632, and the angiotensin II type 1 receptor (AT(1)R) inhibitor irbesartan. Moreover, actin fiber staining showed that aldosterone significantly increased actin fiber formation in HSCs. Pre-incubating with spironolactone, Y27632, or irbesartan inhibited the aldosterone-induced actin fiber reorganization. Molecularly, the effect of aldosterone on activation of HSC contraction was mediated by phosphorylated myosin light chain (P-MLC) through the RhoA/ROCK-2 signaling pathway. All these inhibitors had the ability to block aldosterone-induced protein expressions in the RhoA/ROCK-2/P-MLC cascade in HSCs. Taken together, our current study suggests that aldosterone induces contraction of activated HSCs through the activation of the RhoA/ROCK-2 signaling pathway. This finding may provide a potential therapeutic target for control of cirrhosis and portal hypertension.